Vaccine . Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine

[tetano]

Vaccine


. 2022 Feb 14;S0264-410X(22)00196-7.
doi: 10.1016/j.vaccine.2022.02.052. Online ahead of print.
Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine


Shohei Yamamoto[SUP] 1 [/SUP], Ami Fukunaga[SUP] 1 [/SUP], Akihito Tanaka[SUP] 2 [/SUP], Junko S Takeuchi[SUP] 3 [/SUP], Yosuke Inoue[SUP] 1 [/SUP], Moto Kimura[SUP] 3 [/SUP], Kenji Maeda[SUP] 4 [/SUP], Gohzoh Ueda[SUP] 5 [/SUP], Tetsuya Mizoue[SUP] 6 [/SUP], Mugen Ujiie[SUP] 7 [/SUP], Wataru Sugiura[SUP] 8 [/SUP], Norio Ohmagari[SUP] 7 [/SUP]



Affiliations

• PMID: 35183384
• DOI: 10.1016/j.vaccine.2022.02.052

Abstract

High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.

Keywords: BNT162b2 vaccine; Fever; Reactogenicity; SARS-CoV-2; Spike IgG titer.